Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

Q1 2025 Management View CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, ...

Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was $15 million for the first quarter ...